INFO & CONTACTS:  +39 02 2390 1

Peritoneal Tumours

Milano
Via Giacomo Venezian, 1, 20133 Milano MI

Marcello Deraco

Dr. Deraco Marcello

Head

Typology: Clinical Area

Specialty: Chirurgia Colon-Retto

The Peritoneal Cancer Research and Treatment Programme has been running at our Institute since 1995 and focuses on scientific research and the clinical management of primary and metastatic tumours of the peritoneum.

This group of tumours includes:

  • Peritoneal Mesothelioma,
  • Peritoneal Pseudomyxoma,
  • Primary Peritoneal Papillary Serous Carcinoma, and Peritoneal Metastases (also known as carcinomatosis) from Colorectal Carcinoma, Gastric Carcinoma and non-neuroendocrine tumours of the cecum and appendix.

Once considered incurable, peritoneal cancers have, over the last two decades, attracted the attention of the medical and scientific community, which has developed treatments that now yield significant results. At our institution, the multidisciplinary approach involving surgeons, medical oncologists, biologists, pathologists, nutritionists and psychologists has enabled us to optimise the study, treatment and management of peritoneal cancers. It is therefore now possible to guarantee the best surgical, medical and biological treatments, and an adequate quality of life for every single patient treated. This is in accordance with the International Guidelines and those of the Lombardy Oncology Network (ROL).

The set of procedures involved in the diagnosis and treatment of peritoneal tumours constitutes a complex, relatively new discipline that is often highly technology-driven and draws primarily on surgical expertise, as well as oncological and biological knowledge. When properly applied, this discipline now makes it possible to determine the optimal treatment based on the biological and histological characteristics and the extent of individual tumours. This initial and essential process is the most complex aspect of patient management and is a fundamental prerequisite for the effectiveness of the treatments available to us. Over time, intensive research and technological innovation have been particularly focused on refining innovative treatments such as Cytoreductive Surgery with Peritonectomy (CRS-PP) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) which, together with medical and biological treatments that are often personalised, make it possible to improve the quantity of life whilst enhancing its quality.

With over 20 years’ experience, the Institute is a Centre of Excellence and a national and international point of reference for patients with peritoneal cancer. Its clinical expertise is underpinned by a high annual volume of multidisciplinary assessments and the treatment of over 800 patients using CRS-PP HIPEC.

NHS “initial consultations” take place on Fridays at the Peritoneal Cancer Clinic. Private consultations are held on an out-of-hours basis.

Appointments can be made:
by calling the Institute’s Central Booking Office on 02 2390 1 (from 8.30 am to 4.00 pm, Monday to Friday)

For all types of booking (including telephone bookings), you must have your NHS card, medical prescription and tax code to hand.

‘Initial consultations’ take place in the General Outpatient Clinic on the ground floor, room G, on Fridays from 08.30 to 11.00

The ‘initial consultation’ may concern:
Patients diagnosed with primary or secondary peritoneal cancer who wish to be treated at the Centre

The patient’s presence clearly enables a comprehensive assessment of the case. In the patient’s absence, opinions on the clinical documentation provided for review may only be given with the patient’s consent.

A referral for an ‘initial surgical consultation’, stating the clinical query, is required. Upon arrival at the Institute, the patient is asked to go to the CUP (ground floor) to register for the consultation.

Given the specific nature of the neoplasms treated by the Department, a review of histological specimens is generally required, with the aim of improving the clinical assessment. It is desirable that both stained and unstained sections of the neoplasm (or paraffin-embedded sections) are available.

The availability of unstained sections or the paraffin block allows, in addition to a more accurate immunohistochemical assessment, certain biomolecular evaluations where deemed useful.

It is essential that the histological specimens are accompanied by a copy of the original histological report.

The clinical process is divided into three key stages:

  1. Patient selection;
  2. Surgical treatment with CRS-PP and HIPEC;
  3. Follow-up.

1. Patient selection
The indication for CRS and HIPEC depends on various factors, including the patient’s age, general condition and comorbidities, the histological type of the peritoneal neoplasm, its histological aggressiveness (tumour grading) and its quantitative extent (PCI). In any case, the main indicator is the potential for radical surgery (cc-score); only patients who are completely resectable (i.e. with no residual disease at the end of the operation) may be considered for treatment. Only a clinical assessment by a team of experts can ensure optimal selection.

2. Surgical treatment of CRS-PP with HIPEC
CRS-PP involves a combination of various surgical procedures, which vary depending on the extent of the tumour. In addition to the removal of the entire parietal peritoneum affected by the disease and the omentum, surgery may include major visceral resections with the aim of removing all macroscopically visible tumour tissue. HIPEC offers a dual advantage consisting of the administration of high doses of chemotherapeutic agents directly to the tumour site and the tumour-killing effect of hyperthermia. Finally, there is a synergistic interaction between the two mechanisms, resulting in an effect greater than the sum of its parts. Patients referred for surgical treatment receive appropriate care in the General Surgery Oncology Unit 2 (Colon and Rectal) ward, which comprises 24 beds in twin rooms, all equipped with en-suite bathrooms, air conditioning, TV, telephone and Wi-Fi, as well as four different outpatient clinics dedicated to diagnostics and follow-up.

3. Follow-up
Follow-up appointments are essential for assessing the effectiveness of treatment and, where necessary, detecting any recurrence at an early stage. Following discharge, patients are monitored on an outpatient basis through clinical examinations, diagnostic tests and blood tests. The frequency of check-ups depends on the biological aggressiveness of the disease, the stage of the disease and the time elapsed since surgery. Generally, a check-up is carried out every 4 months for the first two years, every 6 months from the second to the fifth year, and annually from the fifth year onwards.

Scientific research is the main driving force behind the unit’s activities.
Clinical and biological research is carried out through various research projects, approved by the Scientific Ethics Committee and funded by national and international institutions (the Ministry of Health, the National Organization for Rare Diseases (NORD-US)), which focus on various peritoneal neoplastic conditions.
These projects, some of which are multicentre, involve various departments such as Pathology, Experimental Oncology, Nuclear Medicine, Medical Oncology and Radiology within the context of clinical and translational research.

Current Projects:

  1. ‘Pseudomyxoma peritonei: optimising treatment by exploring the links between oncogene mutations and inflammation’ GRANT (AIRC – Italian Association for Cancer Research) 2016–2019;
  2. Evaluation of peritonectomy and hyperthermic perfusion in patients with pseudomyxoma peritonei or mesothelioma: a phase II study. Ministry of Health – IRCCS Current Research – New Frontiers in Oncological Surgery and Rehabilitation, project no. 7.13;
  3. Phase II Randomised Study to evaluate a systematic surgical revision approach, combined with intraperitoneal hyperthermic chemotherapy and possible cytoreductive surgery, versus standard follow-up in patients at high risk of developing peritoneal carcinomatosis from colorectal cancer; Spontaneous Study;
  4. Aminolevulinic acid-mediated photodynamic technique in patients with diffuse malignant peritoneal mesothelioma and peritoneal metastasis from colorectal cancer: results of a Phase I and biological study. Institutional Research Grant INT 2017–2019.

Completed Projects:

  1. Effects of high intra-abdominal pressure on tissue diffusion and the pharmacokinetics of cisplatin during HIPEC (AIRC Grant 2013–2017);
  2. Peritoneal Mesothelioma: Optimising Outcomes through the Integration of New Prognostic Factors and Potential Therapeutic Targets in an Individualised Treatment Approach Based on Molecular Characterisation and Chemosensitivity Profiles in Primary Cultures. Targeted Research Grant 2009 Project Code: RF-2009-1546664 Duration 2011–2016;
  3. Pseudomyxoma Peritonei:  Prognostic Analysis of Micro-RNA and Other Biological Factors Using Tissue Microarray GRANT NORD's MAC 2011 pseudomyxoma peritonei grant award. Duration 2012–2014;
  4. Innovative management of patients with diffuse malignant peritoneal mesothelioma: clinical-diagnostic pathway and new therapeutic targets (ISS National Institute of Health GRANT 2007–2011);
  5. Analysis of survival and biological markers in peritoneal mesothelioma managed with an innovative treatment (GRANT AIRC 2005–2007);
  6. ‘Primary Chemotherapy for Locally Advanced Gastric Carcinoma’. SITILO Phase III Randomised Trial 2002–2004;
  7. A new approach to the treatment of gastrointestinal stromal tumours (GISTs) including induction chemotherapy (CT), cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP): a biological and Phase II clinical study AMENDED TO: Innovative treatment of peritoneal mesothelioma: translational and clinical study (AIRC Grant 2001–2003);
  8. Stage III/IV epithelial ovarian cancer with macroscopic residual disease after first-line chemotherapy: a multicentre prospective randomised study comparing a locoregional approach + systemic chemotherapy versus systemic chemotherapy alone (CIPOV) – (CNR-MIUR/National Centre of Research – University Minister GRANT 2001–2003);
  9. Evaluation of cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic perfusion in patients with pseudomyxoma peritonei or mesothelioma. A phase II clinical study. (Study funded by AIRC 1998–2000;
  10. "Doxorubicin and cisplatin in intraperitoneal hyperthermic antineoplastic perfusion. Phase I-II multicentre study"; 1997-98 (Padua P.I.);
  11. “Intraperitoneal hyperthermic chemotherapy: trial of a new technique in the treatment of carcinomatosis”. (Study funded by AIRC 1994-96).

The facility is a centre recognised by PSOGI for teaching within the ESPSO framework. Dr Marcello Deraco is the Founder and Co-Director of the ESPSO (European School of Peritoneal Surface Oncology), which is a joint venture between the European Society of Surgical Oncology (ESSO) and the Peritoneal Surface Oncology Group (PSOGI). The school aims to train young surgeons who wish to specialise in peritoneal cancer, using an innovative methodology that involves one-to-one mentoring by an expert for each candidate, alongside a programme of clinical and scientific work. The school was inaugurated in 2014, is based in Brussels at the ESSO, involves a selection process for candidates, and leads to a certification attesting to the completion of the training. To date, 15 candidates have already been certified and around 30 candidates are currently enrolled.

  • Peritoneal Mesothelioma,
  • Peritoneal Pseudomyxoma,
  • Primary Peritoneal Papillary Serous Carcinoma and Peritoneal Metastases (also known as carcinomatosis) from colorectal carcinoma, gastric carcinoma and non-neuroendocrine neoplasms of the cecum and appendix.

Deraco Marcello
Head

Dott. Baratti Dario
Doctor

Prof. Kusamura Shigeki
Doctor

Dott. Guaglio Marcello
Doctor

Personale amministrativo e di segreteria:
Roberta Aceto

Last update: 23/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe